TY - JOUR
T1 - Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents
AU - Zheng, Qi Huang
AU - Fei, Xiangshu
AU - Liu, Xuan
AU - Wang, Ji Quan
AU - Bin Sun, Hui
AU - Mock, Bruce H.
AU - Lee Stone, K.
AU - Martinez, Tanya D.
AU - Miller, Kathy D.
AU - Sledge, George W.
AU - Hutchins, Gary D.
N1 - Funding Information:
This work was partially supported by the Susan G. Komen Breast Cancer Foundation grant IMG 2000 837 (to QHZ), the Indiana University American Cancer Society (ACS) Institutional Grant Committee grant IRG-84–002-17 (to QHZ), the Indiana University Cores Centers of Excellence in Molecular Hematology (CCEMH) pilot and feasibility (P/F) grant (to QHZ), the National Institutes of Health/National Cancer Institute grant P20CA86350 (to GDH), the Indiana 21 st Century Research and Technology Fund (to GDH). We thank Dr. Rose S. Fife for the MMP assays. The referee’s criticisms and editor’s comments for the revision of the manuscript are greatly appreciated.
PY - 2002/10
Y1 - 2002/10
N2 - A series of [11C]methyl-halo-CGS 27023A analogs (2-F, 1a; 4-F, 1b; 2-Cl, 1c; 3-Cl, 1d; 4-Cl, 1e; 2-Br, 1f; 3-Br, 1g; 4-Br, 1h; 4-I, 1i), novel radiolabeled matrix metalloproteinase (MMP) inhibitors, have been synthesized for evaluation as new potential positron emission tomography (PET) breast cancer imaging agents. The precursors halo-CGS 27023A analogs (2-F, 6a; 4-F, 6b; 2-Cl, 6c; 3-Cl, 6d; 4-Cl, 6e; 2-Br, 6f; 3-Br, 6g; 4-Br, 6h; 4-I, 6i) for radiolabeling were obtained in four steps from starting material amino acid D-valine with moderate to excellent chemical yields. Precursors were labeled by [11C]methyl triflate through 11C-O-methylation method at the aminohydroxyl position under basic conditions and isolated by solid-phase extraction (SPE) purification to produce pure target compounds in 40-60% radiochemical yields (decay corrected to end of bombardment), in 20-25 min synthesis time.
AB - A series of [11C]methyl-halo-CGS 27023A analogs (2-F, 1a; 4-F, 1b; 2-Cl, 1c; 3-Cl, 1d; 4-Cl, 1e; 2-Br, 1f; 3-Br, 1g; 4-Br, 1h; 4-I, 1i), novel radiolabeled matrix metalloproteinase (MMP) inhibitors, have been synthesized for evaluation as new potential positron emission tomography (PET) breast cancer imaging agents. The precursors halo-CGS 27023A analogs (2-F, 6a; 4-F, 6b; 2-Cl, 6c; 3-Cl, 6d; 4-Cl, 6e; 2-Br, 6f; 3-Br, 6g; 4-Br, 6h; 4-I, 6i) for radiolabeling were obtained in four steps from starting material amino acid D-valine with moderate to excellent chemical yields. Precursors were labeled by [11C]methyl triflate through 11C-O-methylation method at the aminohydroxyl position under basic conditions and isolated by solid-phase extraction (SPE) purification to produce pure target compounds in 40-60% radiochemical yields (decay corrected to end of bombardment), in 20-25 min synthesis time.
KW - Breast cancer
KW - Carbon-11
KW - Matrix metalloproteinase inhibitor
KW - Positron emission tomography
KW - Radiotracer
KW - [C]Methyl-halo-CGS 27023A analogs
UR - http://www.scopus.com/inward/record.url?scp=0036792110&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036792110&partnerID=8YFLogxK
U2 - 10.1016/S0969-8051(02)00338-4
DO - 10.1016/S0969-8051(02)00338-4
M3 - Article
C2 - 12381456
AN - SCOPUS:0036792110
SN - 0969-8051
VL - 29
SP - 761
EP - 770
JO - Nuclear Medicine and Biology
JF - Nuclear Medicine and Biology
IS - 7
ER -
